Treatment of Aggression in Conduct Disorder with ADHD

Pharmacological Interventions

The American Academy of Child and Adolescent Psychiatry recommends adding divalproex sodium (20-30 mg/kg/day divided BID-TID) as the next medication for persistent aggressive outbursts despite adequate trials of stimulants, guanfacine, and atypical antipsychotics, targeting therapeutic blood levels of 40-90 mcg/mL 1, 2
The treatment guidelines suggest that stimulants should be optimized to adequate doses of both methylphenidate and amphetamine preparations at maximum tolerated doses for 4-6 weeks each before adding another medication 3, 4
Atypical antipsychotics, such as risperidone, should be titrated to 1.5-2 mg/day for at least 6-8 weeks at therapeutic doses before considering alternative treatments 1, 5
Lithium carbonate may be considered as an alternative if divalproex is contraindicated or not tolerated, particularly if there is a family history of lithium response 1
The evidence suggests that divalproex sodium is effective for reducing aggression scores by 70% after 6 weeks at therapeutic levels 3, 4, 1

Intensive behavioral therapy, including parent management training and specific techniques such as trigger identification and calming strategies, is a non-negotiable component of treatment alongside medication changes 5, 2
Environmental assessment and modification of specific triggers and warning signs are also crucial in managing aggression 5, 2

Critical monitoring of medication response, liver enzymes, and metabolic syndrome risk is necessary when using divalproex sodium or lithium carbonate 1, 2
Medication adherence should be carefully monitored, and family involvement in supervised administration may be necessary 1
The treatment guidelines recommend avoiding polypharmacy pitfalls by trialing each medication class for 6-8 weeks at therapeutic doses/levels before declaring failure 1, 2

Reactive aggression may respond better to mood stabilizers like divalproex, while proactive aggression may require more intensive psychosocial interventions 1
If aggression remains severe despite optimized treatment, consideration of higher levels of care, such as intensive in-home therapies, partial hospitalization, or inpatient admission, may be necessary 1, 3, 4

The American Academy of Child and Adolescent Psychiatry recommends a clear rationale before using medication combinations, and there is limited support for combining two mood stabilizers as an initial treatment approach in children 6
The American Academy of Child and Adolescent Psychiatry suggests that combining two mood stabilizers may be considered in bipolar disorder in adults, but this patient has conduct disorder and ADHD, not bipolar disorder 6

Basing treatment decisions on theories about covering multiple mechanisms has rudimentary support at best and may put patients at risk for unnecessary medication combinations 6
The prescriber who does not appreciate the need for combined psychosocial and psychopharmacological treatment may unnecessarily expose the child to increasingly complex pharmacological strategies 6

Multimodal approaches combining medications with behavioral interventions are recommended by guidelines from the American Academy of Child and Adolescent Psychiatry 6

Do not assume "more medications = better coverage"—systematic optimization of each agent is more important than adding multiple agents, according to the American Academy of Child and Adolescent Psychiatry 6
Do not combine two mood stabilizers without clear evidence-based rationale—this increases adverse effect burden without proven benefit, as stated by the American Academy of Child and Adolescent Psychiatry 6
Do not skip behavioral interventions—medication alone is insufficient for conduct disorder with ADHD, as recommended by the American Academy of Child and Adolescent Psychiatry 6

Methylphenidate produces a ≈ 49 % positive response for hyperactivity versus 15.5 % with placebo in children with autism spectrum disorder, and yields large reductions in aggressive symptoms in school settings (Cohen’s d = 1.0) 7.

Adding risperidone to optimized stimulant therapy results in a 69 % positive response for aggression compared with 12 % on placebo in autism studies, representing the strongest controlled‑trial evidence for aggression reduction (high‑quality evidence) 7.
Recommended risperidone dosing starts at 0.5 mg/day and is titrated to a target of 1.5–2 mg/day; mean effective doses in trials ranged from roughly 1.2 to 2.9 mg/day (moderate evidence) 7.
Frequently observed adverse effects of risperidone include an average weight gain of about 2.8 kg over six weeks, somnolence in ≈ 51 % of patients, headache in ≈ 29 %, increased appetite, and risks of metabolic syndrome, movement disorders, and elevated prolactin levels (moderate evidence) 7.